NICE TA498 Lenvatinib with everolimus for previously treated advanced renal cell carcinoma (decision date - February 2018)
NICE TA535 - Lenvatinib and sorafenib for treating differentiated thyroid cancer after radioactive iodine (decision date - September 2018
NICE TA551: for untreated advanced hepatocellular carcinoma (decision date - January 2019)
NICE TA858 - Lenvatinib with pembrolizumab for untreated advanced renal cell carcinoma. NHSE commissioned. (Decision date - February 2023)
Red Drug Classifications
1: Requiring specialist assessment to enable patient selection, initiation and ongoing treating
2: Requiring long term on-going monitoring of efficacy by a specialist and not suitable for shared care
3: Requiring long term on-going monitoring of toxicity by a specialist (either because of difficulty in recognising side effects or high cost of investigations to identify toxicity)
8. NHS England commissioned – to be used in line with NHSE commissioning intentions